Name: Robert L. Martuza, M.D.
Office Address: Higgins Professor of Neurosurgery
Chief, Neurosurgery Service
Massachusetts General Hospital WHT502
55 Fruit Street, Boston, MA. 02114-2696
Place of Birth: Wilkes-Barre, PA (USA)
Date of Birth: July 1, l948
1969 B.A. Bucknell University, Lewisburg, PA
1973 M.D. Harvard Medical School, Boston, MA
Internship and Residencies:
1973-1974 Intern in General Surgery,
Massachusetts General Hospital, Boston, MA
1975-1979 Resident in Neurosurgery,
Massachusetts General Hospital, Boston, MA
1979-1980 Chief Resident in Neurosurgery,
Massachusetts General Hospital, Boston, MA
1972-1973 Student Research Fellow in Virology (Tumor virology; Dr. Paul Black),
Massachusetts General Hospital
1974-1975 Clinical and Research Fellow in Neurosurgery
Neurosurgical Oncology, Massachusetts General Hospital
Licensure and Certification:
1976 Massachusetts Medical License Registration
(39007; issued 1/30/76)
1983 American Board of Neurological Surgeons
(Board certified, May l983)
1985 Fellow, American College of Surgeons
1980-1981 Instructor in Surgery, Harvard Medical School
1981-1986 Assistant Professor of Surgery, Harvard Medical School
1986-1991 Associate Professor of Surgery, Harvard Medical School
1991-2000 Professor and Chairman, Department of Neurosurgery,
2000-present Higgins Professor of Neurosurgery, Harvard Medical School
1980-1981 Assistant in Neurosurgery, Massachusetts General Hospital
1981-1986 Assistant Visiting Neurosurgeon, Massachusetts General Hospital
1987-1991 Associate Visiting Neurosurgeon, Massachusetts General Hospital
1991-2000 Professor and Chairman, Department of Neurosurgery,
Georgetown University Hospital
2000-present Chief, Neurosurgery Service, Massachusetts General Hospital
Other Professional Positions and Major Visiting Appointments:
1980-1991 Director, Neurofibromatosis Clinic, Massachusetts General Hospital
1988-1991 Co-director, MGH Brain Tumor Center
1992-2000 Director, Georgetown Brain Tumor Center
1999-2000 Associate Director for Clinical Research
Lombardi Cancer Center, Georgetown University
2000-present Director, Pappas Center for Neuro-Oncology, MGH
2005-present Board of Trustees, Massachusetts General Physicians Organization, Inc.
Principal Clinical and Hospital Service Responsibilities:
1980-1982 Emergency Ward Committee, Massachusetts General Hospital
1980-1983 Neurosurgical Intensive Care Unit Committee
Massachusetts General Hospital
1980-1983 Co-director of Neurosurgical Intensive Care Unit
Massachusetts General Hospital
1981-1983 Subcommittee Review for Research Proposals,
Massachusetts General Hospital
1981-1991 Cancer Affairs Committee, Massachusetts General Hospital
1981-1984 CT Subcommittee, Massachusetts General Hospital
1984-1986 Chairman, Laser Safety Committee,
Massachusetts General Hospital
1987-1988 Chairman, Ad Hoc Committee on Lasers,
Massachusetts General Hospital
1989-1991 General Clinical Research Center Advisory Committee, Massachusetts
1989-1991 MGH Laser Committee
1991-2000 Georgetown Operating Room Committee
1991-2000 Georgetown Executive Faculty Committee
1991-2000 Georgetown Executive Staff Committee
1992 Georgetown Ophthalmology Chairman Search Committee
1993 Fiscal Affairs Committee, Georgetown Faculty Practice Group
1993 Georgetown Endocrinology Chief Search Committee
1993-1998 Georgetown Space Utilization Committee
1993-1998 Georgetown, Internal Advisory Board for The Program
in Cognitive and Computational Sciences
1994 Chair, Search Committee for Chair of Neuroscience Department,
1994-1999 Staff Appointments Committee, Georgetown University Medical Center
1999-2000 Associate Director for Clinical Research Lombardi Cancer Center,
2000 -present Managed Care Committee, Massachusetts General
2000-present Executive Committee on Research, Massachusetts General Hospital
2000-present Partners Research Council, Partners Healthcare
2001-present General Executive Committee, The Massachusetts General Hospital
2005 Member, Search Committee for Neurosurgical Chief, Beth Israel
Deaconess Medical Center
2006-present Clinical Co-Chair, MGH Vascular Center
Major Committee Assignments:
National and Regional:
1981-1991 Medical Advisory Board of the National Neuro-fibromatosis Foundation,
New York, New York
1983 Joint Committee on Education, Congress of Neurological Surgeons
and American Association of Neurological Surgeons
1984 Member of Executive Committee, Joint Section on Tumors,
Congress of Neurological Surgeons, American Association of Neurological
1985 Subcommittee on Research of Brain Tumors, Congress of Neurological
1986-1990 Co-Chairman of Research Advisory Board, National Neurofibromatosis
1987 Joint Subcommittee on Research, Congress of Neurological Surgeons,
American Association of Neurological Surgeons
1988-1991 Joint Section on Stereotactic and Functional Neurosurgery
1989 The Academy Resident Award Committee, The American Academy of
1991 First World Health Organization Planning Conference on
1991 Planning committee for NIH Consensus Conference on Acoustic
1991 Ethics and Human Values Committee, American Association of
1991-1992 Co-director, Review and Update in Neurobiology for Neurosurgeons,
Woods Hole, MA
1992 Chairman, The Academy of Neurological Surgery Resident Award
1993-1996 Co-Chair, Technology Assessment Committee, Society of Neurological
1994-1997 Joint Washington Committee, Congress of Neurological Surgeons
1994-1998 Chairman, Decade of the Brain Task Force American Association of
Neurological Surgeons Congress of Neurological Surgeons
1994-2000 National Cancer Advisory Board, Liaison Representative of AANS
1996 Member NIH Site Visit Team, University of Alabama, Birmingham, AL
1997-present Scientific Advisory Board, MediGene, Inc, (Neurovir, Inc.).
1998 NIH Grant Reviewer for NSD-B study section meeting on Pilot Clinical
1998 NIH Grant Reviewer for NCI-F study section on Training Grants in
1998-present American Society of Gene Therapy, coordinating reviewer
1998-1999 Member of NIH/NINDS Brain Tumor Genome Anatomy Project
1999-present Program Committee, American Society of Gene Therapy
1999-present Board of Scientific Counselors, National Institute of Neurological
Disorders and Stroke (NINDS)
2000-present Scientific Advisory Board, Direct Gene, Inc.
2003-present Advisory Board, CEREGENE, Inc.
2003-present Director, American Board of Neurological Surgery
1980-1991 Massachusetts Medical Society
1980-present American Medical Association
1982-1991 American Society for Laser Medicine and Surgery
1982-present Congress of Neurological Surgery
1983-1991; 2000-present New England Neurosurgical Society
1983-1991 Massachusetts Neurosurgical Society
1983-present American Association of Neurological Surgeons
1985-present Fellow of the American College of Surgeons
1986-1991 The New York Academy of Sciences
1986-1991 Massachusetts Chapter, American College of Surgeons
1986-present Society for Neuroscience
1988-present The American Society for Stereotactic and Functional Neurosurgery
1988-present World Society for Stereotactic and Functional Neurosurgery
1988-present Member, Section of Surgery, Royal Society of Medicine
1989-present American Academy of Neurological Surgeons
1991-present American College of Surgeons, Washington, D.C. Chapter
1992-present Society of Neurological Surgery
1992-present D.C. Medical Society
1992-2000 Southern Neurosurgical Society
1995-present The Charles A. Dana Foundation
1997-present American Association for Cancer Research
1998-present American Society of Gene Therapy
2000-2003 Member, Cancer Gene Therapy Committee, American Society
of Gene Therapy
2002-2003 Co-chair, Program Committee, American Society of Gene Therapy
1987-89 Assistant Clinical Editor, Neurofibromatosis Research Newsletter
1989-1999 Editorial Board, Journal of Neuro-oncology
1993-present Editorial Board, Cancer Gene Therapy
1997-present Commentator, Neurologia medico-chirurgica
1997-present Editorial Board, Brain Tumor Pathology
1998-present Editorial Board, Neoplasia
1999-2005 Editorial Board, Journal of Neurosurgery
2000-present Scientific Advisory Board, Encyclopedia of Neuroscience.
Awards and Honors:
1968 Phi Beta Kappa, Bucknell University
1969 Louis Robey Award, Bucknell University
1969 Cum Laude, Chemistry, Bucknell University
1973 Alpha Omega Alpha, Harvard Medical School
1973 Magna Cum Laude (thesis in a special field),
Harvard Medical School
1988 Traveling Fellowship from The Royal College
of Surgeons of England
1989 Von Recklinghausen’s Award for the advancement of medical sciences
in the field of neuro-fibromatosis; from the National Neuro-fibromatosis
1994 Grass Award, Society of Neurological Surgeons
1998 NF, Inc. Scholar Award
1982-1987 Teacher-Investigator Development Award (NS00654)
“Neurofibromatosis: Cellular features, hormonal controls”
1982 Principal Investigator, National Neurofibromatosis Foundation Research
1983-1986 Physician’s Recognition Award, American Medical Association
1983-1986 Principal Investigator, National Institutes of Health Grant
(RO1NS20025) “Hormonal modulation of tumors of neurofibromatosis”
1985-1988 Co-investigator, National Neurofibromatosis Research Grant “DNA
transfection analysis of the tumors of neurofibromatosis” (P.I., L.
1986-1987 Principal Investigator, Whitaker Health Sciences Fund Grant “The
combined treatment of malignant brain tumors with stereo-tactically
applied photodynamic therapy, hyperthermia, and ionizing radiation”
1986-1987 Principal Investigator, National Neuro-fibromatosis Foundation Research
Grant “Melanocyte growth and modulation in
1986-1987 Co-investigator, National Neurofibromatosis Foundation Research
Grant, “Chromosomal alterations in tumors associated with bi-lateral
acoustic neurofibromatosis: a molecular genetic approach focused on
chromosome 22” (P.I., B. Seizinger)
1986-1990 Principal Investigator, renewal of RO1NS20025,”Hormonal modulation
of tumors of neurofibromatosis”
1987-1990 Principal Investigator “Studies of melanocytes in neurofibromatosis and
tuberous sclerosis”. Neurogenetics Center Grant (PO1-NS24279)
1989 Principal Investigator “Evaluation of a two-wavelength laser in
neurosurgery” subcontract via Abiomed,Inc. from National Institutes of
1990-1992 Principal Investigator “Genetic alteration of nervous system tumors”,
project 2 of Neurogenetics Center Grant (l-PO1-NS24279)
1993-1996 Principal Investigator “Molecular targeting of therapy for nervous
system tumors”. (P20-CA60176-01)
1994.1997 Co-Investigator, “Gene delivery to the CNS to modulate epilepsy” (S.
Rabkin, PI)(R01 NS 33342)
1994-1998 Principal Investigator “National CNS Tumor Consortium -
Georgetown/Lombardi Cancer Center” (U01 CA62454)
1994-1998 Principal Investigator, “Genetically engineered viruses for brain tumor
therapy” (R01 NS 32677)
1994.1998 Co-investigator, “Early clinical trials of antiangiogenesis agents” M.
Hawkins, PI (U01 CA62500)
1996.1999 Principal Investigator, subcontract, 3-D Aids to stereotactic brain
cancer surgery (R44 NS32610-03)
1997-1999 Principal Investigator, Pre-clinical studies of G207 (Neurovir, Inc.)
1997-2002 Program Leader, Neuro-oncology, Cancer Center Support Grant,
1998.2000 Co- Investigator, A dose escalating Phase I Study of the treatment
of Malignant Gliomas with G207, a genetically engineered HSV-1
1998-2001 Principal Investigator, “Herpes vectors for prostate cancer therapy”
1998-2003 Principal Investigator, “Herpes virus therapy of prostate cancer”,
Dept. of Defense (DAMD17-98-1-8490)
1998-2007 Principal Investigator, “Genetically engineered viruses
for brain tumor therapy” (R01 NS 32677 -12)
2001-2006 Principal Investigator, “Clinical Research Training Program in
Neuro-Oncology”, National Cancer Institute, (K12-CA90354)
2004-2007 Principal Investigator, “Immunologic Approaches for Oncolytic
Viral Therapy of Prostate Cancer”, Department of Defensive (Idea
Development Award) (W8IXWH-04-1-0254)
2004-2007 Principal Investigator, “HSV Vector Therapy for NF2 Lesions in
Mouse Models” Department of Defense (Therapeutic Development
Award) (W8IXWH-04-1-0237 )
2004-2009 Principal Investigator, “ Genetically engineered viruses for prostate
cancer therapy” (CA102139)
Major Research Interests:
1. Central Nervous System Tumors: Alteration or destruction of tumor cells by genetically
engineered viruses. Studies of etiology, modulation, and treatment of nervous system tumors. Use of
biologic modifiers, gene and viral therapy to treat nervous system tumors.
2. Neurofibromatosis: Clinical aspects; pathogenesis of the meningeal, Schwann cell and glial
tumors. Experimental therapeutics using anti-angiogenesis agents and “nerve-sparing” viral vectors.
3. Cancer Therapy with Viral Vectors: Development of HSV1-derived vectors to treat prostate and
other cancers. Development of “nerve-sparing vectors” for cancer therapy and viral vectors and cell-
specific vectors as oncolytic agents and as in situ anti-cancer vaccines.
4. Molecular Neurosurgery: Use of viral vectors and genetically engineered cells for gene transfer in
vitro and in vivo in order to alter nervous system function and treat intrinsic nervous system and neuro-
1976 Developed and directed a continuing neuro-pathology course for
1980 Instructor in Surgery for Introduction to the Clinic for Harvard Medical
1981-1989 Developed and instructed a lecture and dissection course in
neuroanatomy and peripheral nerve surgery for neurosurgery residents
1983 Developed and directed with the National Neurofibromatosis Foundation
a symposium for physicians and associated health care persons.
“Neurofibromatosis: Clinical care research directions”.
1980-1990 Lecturer, MGH Neurosurgery Post-graduate Course
1990 Organizer, moderator, speaker in section on malignant brain tumors
MGH Neurosurgery Post-graduate Course
1993 Lecturer, Frontiers in Medicine Georgetown Physiology Graduate
1995 Lecturer, Neuroscience Survey Course
1996-1999 Medical student lectures on neurosurgery, Georgetown
1998-1999 Medical student and Neurology resident lectures on CNS tumors
1998-1999 Lecturer, Neuroscience Survey Course, Georgetown University
Invited Lectures and Visiting Professorships
1981 Invited lecturer “Lasers and phototherapy in Neurosurgery”,
1984 Invited lecturer, CT Stereotactic-Surgery, Sponsored by: Division of
Neurosurgery, University of Utah School of Medicine
1987 Invited Guest Speaker, First LINK Conference on Neurofibromatosis,
Runnymeade, England1987-1993 Invited lecturer at Woods Hole
course “Review and Update in Neuroscience for Neurosurgeons”
1988 Visiting Professor and lecturer, The Royal Hallamshire Hospital,
1988 Visiting Fellow and Lecturer, The Frenchay Hospital, Bristol, England
1988 Visiting Fellow and Lecturer, The Midland Centre for Neurosurgery,
1988 Visiting Fellow and Lecturer, Radcliffe Infirmary, Oxford, England
1989 Invited Speaker and Session Chairman, First Meeting of the International
Society on Neurocutaneous Disorders, Tokyo, Japan
1989 Invited Guest Speaker, The American Academy of Neurological
1989 Visiting Professor, Chicago Neurosurgical Center
1990 Visiting Professor, Dartmouth Medical School
1990 Organizer and speaker, First MGH Brain Tumor Workshop
1990 Invited Speaker, Banbury Conference on Neurofibromatosis, Cold
Spring Harbor, NY
1990 Guest Speaker, American Neurological Association, Atlanta
1990 Invited Guest Speaker, 8th
Nikko Brain Tumor Conference, Saga, Japan
1991 Co-director, Woods Hole course “Review and Update in Neuroscience
1991 Browder Memorial Lecture, New York Neurosurgical Society
1992 Arkin Memorial Lectureship, Chicago Children’s Hospital
1992 Invited Guest Speaker, LINK Conference on Neurofibromatosis,
1992 Invited speaker, American Academy of Neurological Surgeons
1992 Invited Guest Speaker, 5th
Canadian Neuro-Oncology Meeting
1992 First Visiting Professor, Carolyn Farb Endowment Fund in
Neurofibromatosis, M.D. Anderson Cancer Center
1992 Invited speaker, Preuss Foundation Seminar, Miami Beach
1993 Invited speaker, Decade of the Brain Symposium
“Advances in the Treatment of Brain Tumors”, Univ. Cincinnati
1993 Invited guest lecturer, Japan Neurosurgery Society, Tokyo
Visiting Professor, Asian Medical Center, Seoul, Korea
1993 Galbraith Lectureship and Visiting Professor, University of Alabama
1993 Janssen Distinguished Lecturer, “Current concepts in brain tumor
biology and therapy”, 21st
Annual Meeting, SNACC,
1993 Invited speaker, Second Conference on Cancer Gene Therapy, San
1993 Invited Lecturer, UCLA post-graduate update on brain tumor therapy,
1993 Invited speaker, Scandinavian Glioma Conference, Copenhagen
1994 Visiting Professor, Emory University
1994 Altman Lecturer, University of Pennsylvania
1994 Keith Visiting Lectureship, University of Toronto
1994 Visiting Professor and guest lecturer University of Chicago
1994 Chairman and lecturer Decade of the Brain Symposium
“Gene Therapy in the Nervous System” 1994 AANS meeting, San Diego
1994 Invited speaker, Preuss Foundation Seminar on Tumor markers for glial
tumors, San Diego CA
1994 Invited speaker, Grass Award Lecture, Society of Neurological
Surgeons, Charlottesville, VA
1994 Invited Lecturer, 7th
Canadian Neuro-oncology Meeting, Calgary
1994 Guest speaker, Canadian Congress of Neurological Sciences, St.
1994 Session leader and guest speaker, Therapeutic approaches to
neurofibromatosis, FASEB conference on neurofibromatosis, Santa
1994 Aitken Memorial Lecture, London, Ontario
1994 Invited speaker, Brain Tumor Symposium on New Therapies,
Hutchinson Cancer Center, Seattle
1994 Invited speaker, Taxin Brain Tumor Symposium, Wistar Institute,
1995 Neuro-oncology Lectureship Visiting Professor, Mayo Clinic
1995 Lecturer, Gene Therapy Series, National Institutes of Health
1995 Invited Speaker and Scientific Committee Member Gene Therapy for
CNS Disorders, Univ. of Pennsylvania, Philadelphia, PA
1995 Session Leader and invited speaker, NNFF International Consortium for
Molecular Biology of NF1 and NF2, Philadelphia, PA
1995 Invited Speaker, “Development of replication competent viruses for
therapy of brain tumors” at the “International Symposium of
Molecular Neurosurgery Based on Gene Therapy” Nagoya, Japan
1995 Invited Speaker and Chair of Gene Therapy Session, The Eleventh
International Conference on Brain Tumor Research and Therapy,
Napa, California, U.S.A.
1995 Invited Speaker, Delaware Neurosurgical Society
1996 Invited Speaker, Huntsman Cancer Center, Salt Lake City, Utah
1996 Invited speaker, Preuss Conference on Gene Therapy for Brain Tumors,
San Diego, CA.
1996 Visiting Professor, Jefferson Medical College, Philadelphia, PA
1996 Invited lecturer, Univ. Michigan Cancer Center, Ann Arbor, MI
1996 Invited lecturer, Univ. So. Carolina, Charleston, SC
1996 Chair, AANS Decade of the Brain Symposium,
“Watching the Brain Work”, Minneapolis, Minn.
1996 Invited Speaker and Moderator of section onCNS Gene Therapy, TIGR
Gene Therapy Conference, Hilton Head, NC
1996 Chair, Section on Experimental Therapeutics for NF, FASEB
Conference on NF, Aspen, CO
1996 Visiting Professor, Henry Ford Hospital, Detroit, MI
1996 Invited speaker, FDA/NIH conference on Gene Therapy, Bethesda, MD
1997 Pennathur Sundarum Memorial Lecturer, Herpes Virus Therapy of
Cancer, Massachusetts General Hospital, Boston
1997 Invited Speaker, NIH Conference on Herpes Vectors
1997 Visiting Professor, Wake Forest University Medical Center (formerly
Bowman-Gray Medical School)
1997 Invited Lecturer, New York University post graduate course, “A Systems
Approach to Glial Neoplasms”
1997 Speaker and symposium moderator, “State of the Art Treatment of Brain
Tumors”; American Brain Tumor Association and
Childhood Brain Tumor Foundation, Washington, D.C.
1997 Invited speaker, Workshop on NF2: Present and Future,Bethesda, MD
1997 Invited Lecturer, Wood’s Hole RUNN course
1998 Invited speaker, AANS Tumor Satellite Meeting, Phila., PA
1998 Invited speaker, American Society of Gene Therapy, First Annual
Meeting, Seattle, WA. “Herpes virus targeting of glioblastoma”
1998 Invited speaker, First International Congress, Genetics in
Neuroscience, Terni, Italy
1998 Invited speaker, CaPCURE Annual Research Retreat
1998 Invited Lecturer, Wood’s Hole RUNN course
1999 Chairman and speaker of session on “Neurocutaneous Syndromes”,
Congress of Neurological Surgeons meeting, Seattle
1998 Invited Lecturer, New York University post graduate course, “A
Systems Approach to Glial Neoplasms”
1998 Invited lecturer, Institute for Human Gene Therapy Annual Retreat,
1999 Visiting Professor and Invited speaker, Johns Hopkins Medical
School, Dept. Neurosurgery
1999 The First Annual Arthur and Sonia Labatt Brain Tumor Research
Center Academic Lecturer, Toronto
1999 Invited speaker, Second US-Japan Gene Therapy Conference,
1999 Invited Speaker, “Conditionally replicating herpes vectors for tumor
therapy”, Amer. Assoc. for Cancer Research 90th
1999 Chair, Cancer I Session, American Society of Gene Therapy,
Second Annual Meeting, Washington, DC
1999 Invited speaker, International Heresvirus Workshop, Cambridge, MA
1999 Invited Speaker, “Development of herpes vectors for cancer therapy,”
National Cancer Institute Phase I Meeting, Bethesda, MD
1999 Invited presenter, CaPCURE Annual Research Retreat
1999 Visiting Professor, Saga Medical School, Saga, Japan
1999 Visiting Professor, Nagoya Medical School, Nagoya, Japan
1999 Honored Guest Speaker, 58th
Japan Neurosurgical Society, Tokyo
2000 Invited Speaker, RUNN Course, Woods Hole, MA
Invited Speaker, “Development of herpes vectors for abnormal
prostate cancer”, CaPCURE Retreat, Lake Tahoe, Nevada
2001 Invited Speaker, Second International Symposium on Genetic
Anticancer Agents, Valencia, Spain
2001 Invited speaker, CaPCURE Eighth Annual Scientific Retreat, Lake
2002 Invited Speaker, 93rd
Annual Meeting, American Association for
Cancer Research, San Francisco, CA
2002 Invited Speaker and Moderator, Annual Meeting, American Association
of Neurological Surgeons, Chicago, Il.
2002 Invited Speaker, 53rd
Annual Meeting of the German Society of
Neurosurgery, Halle/Saale, Germany
2002 Invited Speaker, Third International Symposium on Genetic
Anticancer Agents, Amsterdam, The Netherlands
2002 Invited Speaker, Japan Neurosurgical Society 61st
2002 Keiji Sano Lectureship, Teikyo University School of Medicine,
2002 Invited Speaker, Brain Tumor Forum, Nagoya Brain Tumor
Society, Nagoya Japan
2003 Invited Speaker, Oncolytic Viruses as Cancer Therapeutics Conference,
Banff, Alberta Canada
2003 Invited Speaker, 15th
International Conference on Brain Tumor Research and
Therapy, Sorrento, Italy
2003 Visiting Professor/Speaker, Departments of Medicine and Surgery and of
Neurosurgery, “La Sapienza” (University of Rome), Policlinico Umberto I
Hospital, Rome, Italy
2004 Invited speaker, Tenth Annual Meeting of the Blood-Brain Barrier
Disruption Consortium, Bend, Oregon
2004 Keynote Speaker, 5th
Annual Meeting of the Japan Molecular Neurosurgical
Meeting, Tokyo, Japan
2004 Frank P. Smith Visiting Professor, University of Rochester
Medical School, Rochester, New York
2004 Keynote Speaker, 3rd
Meeting of the Asian Society
for Neuro-Oncology and 3rd
Shanghai International Conference of
Neurosurgery (Joint Conference), Shanghai, China
2004 Invited Speaker, Beijing Tiantan Hospital and Beijing
Neurosurgical Institute, Beijing, China
2005 Keynote Speaker, Japan Neurological Society, Yokohama, Japan
2005 Keynote Speaker, RUNN Course, Woods Hole, MA
2005 Lecturer, Harvard Medical School, Course on Brain Tumors,
Inventions and Patents
1. Inhibition of neurofibrosarcoma growth and angiogenesis (patent filed 1990; patent issued July 18,
2000; # 6,090,794)
2. Viral mediated destruction of neoplastic cells (patent filed 1990)
3. Viral targeted destruction of neoplastic cells (patent filed 1990)
4. Transfer and expression of gene sequences into central nervous system cells using herpes
simplex virus mutants with deletions in genes for viral replication (patent filed 1992)
5. Replication-competent herpes simplex-1 virus mediates destruction
of neoplastic cells (patent filed 1994; patent issued Dec.17, 1996; #5,585,096)
6. Tumor- or cell-specific herpes simplex viral replication (patent filed 1995; patent issued
Mar.17, 1998; #5,728,379)
7. Use of herpes vectors for tumor therapy (application #60/055,142; filed 08/12/97)
8. Implanting HSV-TK Retrovirus Producing Cells To Treat Tumors (patent filed 1995, patent
9. Implantation of HSV-TK Retrovirus Producer Cells to Destroy Glioma (patent filed 1995, patent
10. Transfer and Expression of Gene Sequences into Nervous System Cells Using Herpes Simplex
Virus Mutants with Deletions in Genes for Viral Replication (patent filed 1994, patent issued 2003
11. Replication-Competent Herpes Simplex Virus Mediates Destruction of Neoplastic Cells (patent
filed 2000, patient issued 2004 6,699,468 B1)
Original Reports (Published and In Press)
1. Martuza RL, Black PH, Kornblith PL, Dohan FC Jr. Evidence for presence of a virus in
glioblastoma multiforme cells. Surg For 1973; 24: 459-61.
2. Martuza RL, Shamberger RC, Phillips JP, Kornblith PL, Dohan FC Jr, Hochberg FH. A
lymphocyte-dependent antibody assay for detection of antibodies to human glioma cells. Surg For
1975; 26: 492-4.
3. Martuza RL, Proffitt MR, Moore MB, Dohan CF Jr. Evaporation as a cause of positional
differences in cell plating and growth in microtiter plates. Transplantation 1976 Mar; 2l(3):
4. Stewart RM, Martuza RL, Baldessarini RJ, Kornblith PL. Glutamate accumulation by human
gliomas and meningiomas in tissue culture. Brain Res 1976 Dec24; 118(3): 441-52.
5. Phillips JP, Sujatanond M, Martuza RL, Quindlen EA, Wood WC, Kornblith PL, Dohan FC Jr.
Cytotoxic antibodies in preoperative glioma patients: A diagnostic assay. Acta Neur 1976; 35(1-
6. Martuza RL, Kornblith PL, Liszczak TM. Characteristics of human optic gliomas in tissue
culture. J Neurosurg 1977 Jan; 46(1): 78-84.
7. Chapman PH, Martuza RL, Poletti CE, Karchmer AW. Symptomatic spinal epidural lipomatosis
associated with Cushing’s Syndrome. Neurosurg 1981 Jun; 8(6): 724-7.
8. Martuza RL, Ojemann RG, Shillito J Jr, Wepsic JG. Facial pain associated with a middle fossa
arachnoid cyst. Neurosurg 1981 Jun; 8(6): 712-16.
9. Martuza RL, MacLaughlin DT, Ojemann RG. Specific estradiol binding in schwannomas,
meningiomas, and neurofibromas. Neurosurg 1981 Dec; 9(6): 665-71.
10. Martuza RL, Ojemann RG. Bilateral acoustic neuromas: clinical aspects, pathogenesis, and
treatment. Neurosurg 1982 Jan; l0(1): l-l2.
11. Conner ES, Martuza RL, Heros RC. Seizures due to metrizamide myelography in patients with
acute cervical spine injury. Neurosurg 1982 Feb: 10(2): 266-7.
12. Martuza RL, Liszczak T, Okun A, Wang T-Y. Human neurofibromas in co-culture with mouse
Ann Proc Elec Micro Soc Amer 1982: 194-195.
13. Martuza RL. Genetics in neuro-oncology. Clin NeurosSurg 1983; 31: 417-40.
14. Nakagawa H, Hori Y, Sato S, Fitzpatrick TB, Martuza RL. The nature and origin of the melanin
macroglobule. J Invest Dermatol 1984; 83(2): 134-9.
15. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: Analysis
of recurrence and progression following neurosurgical resection. J Neurosurg 1984 Jan; 62(1):
16. Granick MS, Martuza RL, Parker SW, Ojemann RG, Montgomery WW. Cerebellopontine angle
meningiomas: Clinical manifestations and diagnosis. Ann Otol Rhinol Laryngol 1985 Jan-Feb;
94(1 Pt 1): 34-8.
17. Jay JR, MacLaughlin DT, Riley KR, Martuza RL. Modulation of meningioma cell growth by sex
steroid hormones in vitro. J Neurosurg 1985 May; 62(5): 757-62.
18. Martuza RL, Miller DC, MacLaughlin DT. Estrogen and progestin binding by cytosolic and
nuclear fractions of human meningiomas. J Neurosurg 1985 May; 62(5): 750-6.
19. Martuza RL, Phillipe I, Fitzpatrick TB, Zwaan J, Seki Y, Lederman J. Melanin macroglobules as
a cellular marker of neurofibromatosis: A quantitative study. J Invest Dermatol 1985 Oct; 85(4):
20. Kostron H, Swartz MR, Miller DC, Martuza RL. The interaction of hematoporphyrin derivative,
light, and ionizing radiation in a rat glioma model. Cancer 1986 Mar 1; 57(5): 964-70.
21. Kostron H, Bellnier DA, Lin CW, Schwartz MR, Martuza RL. Distribution, retention, and
phototoxicity of hematoporphyrin derivative in a rat glioma. Intraneoplastic versus intraperitoneal
injection. J Neurosurg 1986 May; 64(5): 768-74.
22. Cohen AM, Wood WC, Bamberg M, Martuza R. Cytotoxicity of human brain tumors by
hematoporphyrin derivative. J Surg Res 1986 Jul; 41(1): 81-3.
23. Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorigenesis of
human acoustic neuroma. Nature 1986 Aug 14-20; 322(6080): 644-7.
24. Bouckoms A, Martuza RL, Henderson M. Capgras syndrome with subarachnoid hemorrhage. J
Nerv Ment Dis 1986 Aug; 174(8): 484-8.
25. Brockes JP, Breakefield XO, Martuza RL. Glial growth factor-like activity in Schwann cell
tumors. Ann of Neurol. 20(3): 3l7-22, 1986 Sep.
26. Steichen JD, Dashner K, Martuza RL. Distribution of hematoporphyrin derivative in canine
glioma following intraneoplastic and intraperitoneal injection. J Neurosurg 1986 Sep; 65(3):
27. Jacoby L, Martuza RL. DNA transfection analysis of the tumors of neurofibromatosis. Ann NY
Acad Sci 1986; 486: 333-5.
28. Jay JR, MacLaughlin DT, Badger TM, Miller DC, Martuza RL. Hormonal modulation of
Schwann cell tumors. I. The effects of estradiol and tamoxifen on methylnitrosourea-induced rat
Schwann cell tumors. Ann NY Acad Sci 1986; 486: 371-82.
29. Fitzpatrick TB, Martuza RL. Clinical diagnosis of von Recklinghausen’s neurofibromatosis. Ann
NY Acad Sci 1986; 486: 383-5.
30. Seizinger BR, Rouleau G, Ozelius LJ, Lane AH, St. George-Hyslop P, Huson S, Gusella JF,
Martuza RL. Common pathogenetic mechanism for three tumor types in bilateral acoustic
neurofibromatosis. Science 1987 Apr 17; 236(4799): 317-9.
31. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Faryniarz AG, Chao MV, Huson S, Korf BR,
Parry DM, Pericak-Vance MA, Collins FS, Hobbs W, Falcone BG, Iannazzi JA, Roy FC, St
George-Hyslop PH, Tanzi RE, Bothwell MA, Upadhyaya M, Harper P, Goldstein AE, Hoover
DL, Bader JL, Spence MA, Mulvihill JJ, Aylsworth AS, Vance JM, Rossenwasser GOD, Gaskell
PC, Roses AD, Martuza RL, Breakefield XO, Gusella JF. Genetic linkage of von Recklinghausen
neurofibromatosis to the nerve growth factor receptor gene. Cell 1987 Jun 5; 49(5): 589-94.
32. Seizinger BR, de la Monte S, Atkins L, Gusella JF, Martuza RL. Molecular genetic approach to
human meningioma: Loss of genes on chromosome 22. Proc Nat Acad Sci USA 1987 Aug;
33. Rouleau GA, Wertelecki W, Haines JL, Hobbs WJ, Trofatter JA, Seizinger BR, Martuza RL,
Superneau DW, Conneally PM, Gusella JF. Genetic linkage of bilateral acoustic
neurofibromatosis to a DNA marker on chromosome 22. Nature 1987 Sep 17-23; 329(6136):
34. Nadol JB Jr, Levine R, Ojemann RG, Martuza RL, Montgomery WW, de Sandoval PK.
Preservation of hearing in surgical removal of acoustic neuromas of the internal auditory canal and
cerebellar pontine angle. Laryngoscope 1987 Nov; 97(11): l287-94.
35. Seizinger BR, Martuza RL, Rouleau G, Breakefield XO, Gusella JF. Models for inherited
susceptibility to cancer in the nervous system: A molecular-genetic approach to neurofibromatosis.
Develop Neurosci 1987; 9(3): 144-53.
36. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JWM,
Collins D, Majoor-Krakuer D, Bonner T, Mathew C, Rubenstein A, Halperin J, McConkie-Rosell
A, Green JS, Trofatter JA, Ponder BA, Eierman L, Bowmer MI, Schimke R. Oostra B, Aronin N,
Smith DI, Drabkin H, Waziri MH, Hobbs WJ, Martuza RL, Conneally PM, Hsia YE, Gusella JF.
Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell
carcinoma. Nature 1988 Mar 17; 332: 268-9.
37. Kostron H, Swartz MR, Martuza RL. Photodynamic therapy is potentiated by Co60
intratumoral injection of hematoporphyrin derivative. J Neuro-oncol 1988 Sep; 6(2): 185-91.
38. Seizinger BR, Farmer GE. Haines JL. Ozelius LJ. Anderson K. Korf BR. Parry DM.
Pericak-Vance MA. Mulvihill JJ. Menon A. Hobbs WJ. Martuza RL. Gusella JF. Flanking
markers for the gene causing von Recklinghausen neurofibromatosis (NF-l). Amer J Hum Gen
1989 Jan; 44(1): 30-2.
39. el-Azouzi M, Chung RY, Farmer GE, Martuza RL, Black, PL, Rouleau GA, Hettlich C, Hedley-
Whyte ET, Zervas NT, Panagopoulos K, Nakamura Y, Gusella JF, Seizinger BR. Loss of distinct
regions on the short arm of chromosome 17 associated with tumorigenesis of human astrocytomas.
Proc Nat Acad Sci USA 1989 Sep; 86(18): 7186-90.
40. Medhkour A, Van Roey M, Sobel RA, Fingert HJ, Lee J, Martuza RL. Implantation of human
meningiomas into the subrenal capsule of the nude mouse: A model for studies of tumor growth. J
Neurosurg 1989 Oct; 71(4): 545-50.
41. Louis DN, Hedley-Whyte ET, Martuza RL. Sarcomatous proliferation of the vasculature in a
subependymoma. Acta Neuropath 1989; 78(3): 332-5.
42. Rouleau GA, Seizinger BR, Wertelecki W, Haines JL, Superneau DW, Martuza RL, Gusella JF.
Flanking markers bracket the neurofibromatosis type 2 (NF2) gene on chromosome 22. Amer J
Hum Gen 1990 Feb; 46(2): 323-8.
43. Logan JA, Seizinger BR, Atkins L, Martuza RL. Loss of the Y chromosome in meningiomas: a
molecular genetic approach. Canc Gen & Cytogen 1990 Mar; 45(1): 41-7.
44. Lee JK, Kim TS, Chiocca EA, Medhkour A, Martuza RL. Growth of human Schwannomas in the
subrenal capsule of the nude mouse. Neurosurg 1990Apr; 26(4): 598-605.
45. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE,
Freiman RN, Lee JK, Li FP, Barker DF, Ledbetter DH, Kleider A, Martuza RL, Gusella JF,
Seizinger BR. Chromosome 17p deletions and p53 gene mutations associated with the formation
of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Nat Acad Sci
USA 1990 Jul; 87(14): 5435-9.
46. Chiocca EA, Choi BB, Cai W, DeLuca NA, Schaffer PA, DiFiglia M, Breakefield XO, Martuza
RL. Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex
virus mutants. New Biologist 1990 Aug; 2(8): 739-46.
47. Lee JK, Choi B, Sobel RA, Chiocca EA, Martuza RL. Inhibition of growth and angiogenesis of
human neurofibrosarcoma by heparin and hydrocortisone. J Neurosurg 1990 Sep; 73(3): 429-35.
48. Steichen JD, Stewart RB, Louis DN, Choi BB, Kung R, Martuza RL. A new 1.9 micron
wavelength laser for neurosurgery. J Neurosurg 1990 Oct; 73(4): 611-4.
49. Jacoby LB, Pulaski K, Rouleau GA, Martuza RL. Clonal analysis of human meningiomas and
schwannomas. Canc Res 1990 Nov 1; 50(21): 6783-6.
50. Fontaine B, Rouleau GA, Seizinger BR, Jewell AF, Hanson MP, Martuza RL, Gusella JF. Equal
parental origin of chromosome 22 losses in human sporadic meningioma: No evidence for
genomic imprinting. Amer J Hum Gen 1990 Nov; 47(5): 823-7.
51. Jacoby LB, Hedley-Whyte ET, Pulaski K, Seizinger BR, Martuza RL. Clonal origin of pituitary
adenomas. J Neurosurg 1990 Nov; 73(5): 731-5.
52. Short MP, Choi BB, Lee JK, Malick A, Breakefield XO, Martuza RL. Gene delivery to glioma
cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 1990 Nov; 27(3):
53. Louis DN, Hedley-Whyte TE, Martuza RL. Sarcomatous proliferation of the vasculature in a
subependymoma: A follow-up study of sarcomatous dedifferentiation. Acta Neuropath 1990;
54. Steichen JD, Weiss MJ, Elmaleh DR, Martuza RL. Enhanced in vitro uptake and retention of
H-tetraphenylphosphonium by nervous system tumor cells. J Neurosurg 1991 Jan; 74(1): 116-22.
55. Fontaine B, Hanson MP, VonSattel JP, Martuza RL, Gusella JF. Loss of chromosome 22 alleles
in human sporadic spinal schwannomas. Ann Neurol 1991 Feb; 29(2): 183-6.
56. Halliday AL, Sobel RA, Martuza RL. Benign spinal nerve sheath tumors: Their occurrence
sporadically and in neurofibromatosis types 1 and 2. J Neurosurg 1991 Feb; 74(2): 248-53.
57. Seizinger BR, Smith DI, Filling-Katz MR, Neumann H, Green JS, Choyke PL, Anderson KM,
Freiman RN, Klauck SM, Whaley J, Decker H-JH, Hsia YE, Collins D, Halperin J, Lamiell JM,
Oostra B, Waziri MH, Gorin MB, Scherer G, Drabkin HA, Aronin N, Schinzel A, Martuza RL,
Gusella JF, Haines JL. Genetic flanking markers refine diagnostic criteria and provide insights
into the genetics of von Hippel Lindau disease. Proc Nat Acad Sci USA 1991 Apr; 88(7): 2864-8.
58. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human
glioma by means of a genetically engineered virus mutant. Science 1991 May 10; 252(5007):
59. Fontaine B, Sanson M, Delattre O, Menon AG, Rouleau GA, Seizinger BR, Jewell AF, Hanson
MP, Aurias A, Martuza RL, Gusella JF, Thomas G. Parental origin of chromosome 22 loss in
sporadic and NF2 neuromas. Genomics 1991 May; 10(1): 280-3.
60. Ezzedine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, Breakefield XO. Selective
killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus
thymidine kinase gene. New Biologist 1991 Jun; 3(6): 608-14.
61. Jenike MA, Baer L, Ballantine HT, Martuza RL, Tynes S, Giriunas I, Buttolph ML, Cassem NH.
Cingulotomy for refractory obsessive-compulsive disorder: A long-term follow-up of 33 patients.
Arch Gen Psych 1991 Jun; 48(6): 548-55.
62. Chung RY, Whaley JM, Kley N, Anderson KM, Louis D, Menon A, Hettlich C, Freiman R,
Hedley-Whyte ET, Martuza RL, Jenkins R, Yandell DW, Seizinger BR. TP53 gene mutations and
17p deletions in human astrocytomas. Genes, Chromosomes, and Cancer 1991 Sep; 3(5): 323-31.
63. Flexon PB, Nadol JB Jr, Schuknecht HF, Montgomery WW, Martuza RL. Bilateral acoustic
neurofibromatosis (neurofibromatosis 2): a disorder distinct from Von Recklinghausen’s
neurofibromatosis (neurofibromatosis 1). Ann Otol Rhinol Laryngol 1991 Oct; 100(10):
64. Fontaine B, Rouleau GA, Seizinger BR, Menon AG, Jewell AF, Martuza RL, Gusella JF.
Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and
meningioma). Ann NY Acad Sci 1991; 615: 338-43.
65. Huang Q, VonSattel JP, Schaffer PA, Martuza RL, Breakefield XO, DiFiglia M. Introduction of a
foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus
mutants: A light and electron microscopic study. Exper Neurol 1992 Mar; 115(3): 303-16.
66. Poon WS, Schomacker KT, Deutsch TF, Martuza RL. Laser-induced fluorescence: Experimental
intraoperative delineation of tumor resection margins. J Neurosurg 1992 Apr; 76: 679-86.
67. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung RY, Martuza RL,
Schoenfield DA, Yasargil MG, Wiestler OD, Seizinger BR. Association of epidermal growth
factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme.
J Neurosurg 1992 Aug; 77(2): 295-301.
68. Narod SA, Parry DM, Parboosingh J, Lenoir GM, Ruttledge M, Fischer G, Eldridge R, Martuza
RL, Frontali M, Haines J, Gusella JF, Rouleau GA. Neurofibromatosis type 2 appears to be a
genetically homogeneous disease. Amer J Hum Genet 1992 Sep; 51(3): 486-96.
69. Lee JK, Sobel RA, Chiocca EA, Kim TS, Martuza RL. Growth of human acoustic neuromas,
neurofibromas and shwannomas in the subrenal capsule and sciatic nerve of the nude mouse. J
Neuro-Oncol 1992 Oct; 14(2): 101-12.
70. Markert JM, Coen DM, Malick A, Mineta T, Martuza RL. Expanded spectrum of viral therapy in
the treatment of nervous system tumors. J Neurosurg 1992 Oct; 77(4): 590-4.
71. Nadol JB Jr, Chiong CM, Ojemann RG, McKenna MJ, Martuza RL, Montgomery WW, Levine
RA, Ronner SF, Glynn RJ. Preservation of hearing and facial nerve function in resection of
acoustic neuroma. Laryngoscope 1992 Oct; 102(10): 1153-8.
72. Takamiya Y, Short MP, Ezzedine ZD, Moolten FL, Breakefield XO, Martuza RL. Gene therapy
of malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine
kinase gene and wild type retrovirus kills other tumor cells. J Neurosci Res 1992 Nov; 33(3): 493-
73. Martuza RL. Molecular Neurosurgery for glial and neuronal disorders. Stereotac & Funct
Neurosurg 1992; 59(1-4): 92-9.
74. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N,
Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL,
MacDonald ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF. A novel Moesin-, Ezrin-,
Radixin-like gene is a candidate for the Neurofibromatosis 2 tumor suppressor. Cell 1993 Mar 12;
75. Takamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL. Inhibition of angiogenesis and
growth of human nerve-sheath tumors by AGM-1470. J Neurosurg 1993 Mar; 78(3): 470-6.
76. Markert JM, Malick A, Coen DM, Martuza RL. Reduction and elimination of encephalitis in an
experimental glioma therapy model with attenuated herpes simplex mutants that retain
susceptibility to acyclovir. Neurosurg 1993 Apr; 32(4): 597-603.
77. Yu JS, Wei MX, Chiocca EA, Martuza RL, Tepper RI. Treatment of glioma by engineered
interleukin 4-secreting cells. Canc Res 1993 Jul 1; 53(13): 3152-8.
78. Takamiya Y, Short MP, Moolten FL, Fleet C, Mineta T, Breakefield XO, Martuza RL. An
experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 1993 Jul;
79. Baer L, Rauch SL, Jenike MA, Cassem NH, Ballantine HT, Manzo PA, Martuza RL.
Cingulotomy in a case of concomitant obsessive-compulsive disorder and Tourette’s syndrome.
Arch Gen Psych 1994 Jan; 51(1): 73-4.
80. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL. AGM-1470 inhibits the growth of human
glioblastoma cells in vitro and in vivo. Neurosurg 1994 May; 34(5): 869-75.
81. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-
hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Canc Res 1994
Aug 1; 54(15): 3963-6.
82. al-Nabulsi I, Takamiya Y, Voloshin Y, Dritschilo A, Martuza RL, Jorgensen TJ. Expression of
thymidine kinase is essential to low dose radiation resistance of rat glioma cells. Canc Res 1994
Nov 1; 54(21): 5614-7.
83. Ahmad S, Mineta T, Martuza RL, Glazer RI. Antisense expression of protein kinase Cα inhibits
the growth and tumorigenicity of human glioblastoma cells. Neurosurg 1994 Nov; 35(5): 904-8;
84. Mineta T, Markert JM, Takamiya Y, Coen DM, Rabkin SD, Martuza RL. CNS tumor therapy by
attenuated herpes simplex viruses. Gene Ther 1994; 1 Suppl 1: S78.
85. New KC, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors for the study of
promoter and gene function in the CNS. Gene Ther 1994; 1 Suppl 1: S79.
86. Baer L, Rauch SL, Ballantine HT Jr, Martuza RL, Cosgrove R, Cassem E, Giriunas I, Manzo PA,
Dimino C, Jenike MA. Cingulotomy for intractable obsessive-compulsive disorder: Prospective
long-term follow-up of 18 patients. Arch Gen Psych 1995 May; 52(5): 384-92.
87. Mineta T, Tabuchi K, Martuza RL. Gene therapy for brain tumors: Experimental treatment of
malignant brain tumors using recombinant herpes simplex virus type 1 (series 7). No Shinkei
Geka – Neurolog Surg 1995 Sep; 23(4): 285-92.
88. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes
simplex virus-1 for the treatment of malignant gliomas. Nature Med 1995 Sep; 1(9): 938-43.
89. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by
G207, a replication-competent multimutated herpes simplex virus 1. Canc Res 1995 Nov 1;
90. Yazaki T, Takamiya Y, Costello PC, Mineta T, Menon AG, Rabkin SD, Martuza RL. Inhibition of
angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J
Neuro-oncol 1995; 23(1): 23-9.
91. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL, Glazer RI.
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α
phosphorothioate oligodeoxynucleotide. Molec Pharmacol 1996 Aug; 50(2): 236-42.
92. Yazaki T, Martuza RL, Rabkin SD. Expression of L1 in primary astrocytes via a defective herpes
simplex virus vector promotes neurite outgrowth and neural cell migration. Molec Brain Res 1996
Dec 31; 43(1-2): 311-20.
93. Menon AG, Rutter JL, VonSattel JP, Snyder H, Murdoch C, Blumenfeld A, Martuza RL, von
Deimling A, Gusella JF, Houseal TW. Frequent loss of chromosome 14 in atypical and malignant
meningioma: Identification of a putative ‘tumor progression’ locus. Oncogene 1997 Feb 6;
94. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for
cell-specific replication. J Virol 1997 Jul; 71(7): 5124-32.
95. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing
thymidine kinase for the treatment of malignant glioma. Canc Gene Ther 1997 Jul-Aug; 4(4):
96. Toda M, Martuza RL, Kojima H, Rabkin SD. In situ cancer vaccination: An IL-12 defective
vector/replication-competent herpes simplex virus combination induces local and systemic
antitumor immunity. J Immunol 1998 May 1; 160(9): 4457-64.
97. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model
by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998 Oct
10; 9(15): 2177-85.
98. New KC, Gale K, Martuza RL, Rabkin SD. Novel synthesis and release of GABA in cerebellar
granule cell cultures after infection with defective herpes simplex virus vectors expressing
glutamic acid decarboxylase. Molec Brain Res 1998 Oct 30; 61(1-2): 121-35.
99. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex as an in situ cancer vaccine for the
induction of specific anti-tumor immunity. Hum Gene Ther 1999 Feb 10; 10(3): 385-93.
100.Miyatake SI, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N,
Hangai M, Martuza RL, Rabkin SD. Hepatoma-specific antitumor activity of an albumin
enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 1999 Apr; 6(4): 564-72.
101.Chahlavi A, Todo T, Martuza RL, Rabkin SD. Replication-competent herpes simplex virus vector
G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia
1999 Jun; 1(2): 162-9.
102.Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT,
Platenberg RC, Manz HJ, Rabkin SD. Attenuated, replication-competent, herpes simplex virus
type-1 mutant G207: Safety evaluation of intracerebral injection in non-human primates. J Virol
1999 Aug; 73(8): 6319-26.
103.Walker JR, McGeagh K, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and
systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes
simplex virus vector G207. Hum Gene Ther 1999, Sep 1;10(13): 2237-43.
104.Mashour GA, Wang HL, Cabal-Manzano R, Wellstein A, Martuza RL, Kurtz A. Aberrant
cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-
1. J Invest Dermatol 1999 Sep; 113(3): 398-402.
105.Chahlavi A, Rabkin SD, Todo T, Sundaresan P, Martuza RL. Effect of prior exposure to HSV-1
on viral vector mediated tumor therapy in immunocompetent mice. Gene Ther 1999 Oct; 6(10):
106.Todo T, Rabkin SD, Chahlavi A, Martuza RL. Corticosteroid administration does not affect viral
oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex
virus tumor therapy. Hum Gene Ther 1999 Nov 20; 10(17): 2869-78.
107.Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, Martuza RL. Systemic
antitumor immunity in experimental brain tumor therapy using a multimutated, replication-
competent herpes simplex virus. Hum Gene Ther 1999 Nov 20; 10(17): 2741-55.
108.Mashour GA, Martuza RL, Kurtz A. Induction of melanogenic abnormalities in NF1+/- mutant
mice by DMBA. J Invest Dermatol 1999 Dec; 113(6): 1133-4.
109.Sandhu FA, Schellinger D, Martuza RL. A vascular sarcoid mass mimicking a convexity
meningioma. Neuroradiol 2000 Mar; 42(3): 195-8.
110.Sundaresan P, Hunter WD, Martuza RL, Rabkin SD. Attenuated, replication-competent herpes
simplex virus type 1 mutant G207: Safety evaluation in mice. J Virol 2000 Apr; 74(8): 3832-41.
111.Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA,
Feigenbaum F, Tornatore C, Tufaro F, Martuza RL. Conditionally replicating herpes simplex
virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther
2000 May; 7(10): 867-74.
112.Todo T, Rabkin SD, Martuza RL. Evaluation of ganciclovir-mediated enhancement of the
antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain
tumors. Canc Gene Ther 2000 Jun; 7(6): 939-46.
113.Lim DJ, Rubenstein AE, Evans DG, Jacks T, Seizinger BG, Baser ME, Beebe D, Brackmann DE,
Chiocca EA, Fehon RG, Giovanni M, Glazer R, Gusella JF, Gutmann DH, Korf B, Lieberman F,
Martuza RL, McClathey AI, Parry DM, Pulst SM, Ramesh V, Ramsey WJ, Ratner N, Rutkowski
JL, Ruttledge M, Weinstein DE. Advances in neurofibromatosis 2 (NF2): a workshop report. J
Neruogenet, 200 Jun: 14(2):63-106. Review.
114.Moulding HD, Martuza RL, Rabkin SD. Clinical mutations in the L1 neural cell adhesion
molecule affect cell-surface expression. J Neurosci 2000 Aug 1; 20(15): 5696-702.
115.Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of
defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating
factor. Molec Ther 2000 Oct; 2(4): 324-9.
116.Todo T, Feigenbaum F, Rabkin SD, Lakeman F, Newsome JT, Johnson PA, Mitchell E, Belliveau
D, Ostrove JM, Martuza RL. Viral shedding and biodistribution of G207, a multimutated,
conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.
Molec Ther 2000 Dec; 2(6): 588-95.
117.Sandhu FA, Martuza RL. Craniofacial hemangiopericytoma associated with oncogenic
osteomalacia: Case report. J Neuro-oncol 2000; 46(3): 241-7.
118.Todo T, Martuza RL, Dallman MJ, Rabkin SD. In situ expression of soluble B7-1 in the context
of oncolytic herpes simplex virus induces potent antitumor immunity. Canc Res 2001 Jan 1;
119.Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A. The angiogenic factor
midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for
neurofibroma-derived cells. Oncogene 2001 Jan 4; 20(1): 97-105.
120.Toda M, Martuza RL, Rabkin SD. Combination suicide/cytokine gene therapy as adjuvants to a
defective herpes simplex virus-based cancer vaccine. Gene Ther 2001 Feb; 8(4): 332-9.
121.Wu A, Mazumder A, Martuza RL, Liu X, Thein M, Meehan KR, Rabkin SD. Biological purging
of breast cancer cells using an attenuated replication-competent herpes simplex virus in human
hematopoietic stem cell transplantation. Canc Res 2001 Apr; 61(7): 3009-15.
122.Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL.
Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type I,
inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 2001 May 20;
123.Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with
enhanced MHC class I presentation and tumor cell killing. Proc Nat Acad Sci USA 2001 May 22;
124.Mashour GA, Moulding HD, Chahlavi A, Khan GA, Rabkin SD, Martuza RL, Driever PH, Kurtz
A. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exper Neurol
2001 May; 169(1): 64-71.
125.Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL. Ionizing
radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous
tumor models of human and murine prostate cancer. Neoplasia (New York) 2001 Sep-Oct; 3(5):
126.Kurtz A, Martuza RL. Antiangiogenesis in neurofibromatosis 1. J Child Neurol 2002 Aug; 17(8):
127.Nikolic B, Feigenbaum F, Abbara S, Martuza RL. Schellinger D. CT changes of an intracranial
granulocytic sarcoma on short-term follow-up. Amer J Roentgenol 2003 Jan; 180(1): 78-80.
128.Weber DC, Chan AW, Bussiere MR, Harsh GR 4th,
Ancukiewicz M, Barker FG 2nd,
Martuza RL, Nadol JB Jr, Chapman PH, Loeffler JS. Proton beam radiosurgery for vestibular
schwannoma: Tumor control and cranial nerve toxicity. Neurosurg 2003 3Sep; 53(3): 577-86.
129.Mashour GA, Driever PH, Hartmann M, Drissel, SN, Shang T, Schart B, Fedlerhoff-Muser U,
Sakuma S, Friedrich RE, Martuza RL, Mautner V-F, Kurtz A. Circulating growth factor levels are
associated with tumorigenesis in neurofibromatosis Type 1. Clin Cancer Research. 2004 Sept,
130. Liu, R, Martuza RL, Rabkin SD., Intracarotid Delivery of Oncolytic HSV Vector G47∆ To
Metastatic Breast Cancer in the Brain. Gene Therapy 2005 Apr 12(8):647-654.
131.Mashour GA, Drissel SN, Frahm S, Farassati F, Martuza RL, Mautner V-F, Kindler-Rohrborn A,
Kurtz A., Differential Modulation of Malignant Peripheral Nerve Sheath Tumor Growth by
Omega-3 and Omega-6 Fatty Acids. Oncogene. 2005 Mar 31; 24(14):2367-74.
132.Kurtz A, Lueth M, Kluwe L, Shang T, foster R, Mautner VF, Hartmann M, Tan DJ, Martuza RL,
Friedrich RE, Driever Ph, Won Lj., Somatic mitochonrial DNA mutations in neurofibromatosis
type 1-associated tumors. Mol Cancer Res., 2004 Aug;2(8):433-41.
133.Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, Drewes LR, Hall WA,
Hoffman JM, Korfel A, Martuza R, Muldoon LL, Peereboom D., Peterson DR, Rabkin SD, Smith
Q, Stevens, GHJ, Neuwelt EA. New Frontiers in Translational Research in Neuro-oncology and
the Blood Brain Barrier: Report of the Tenth Annual Blood-Brain Barrier Disruption consortium
Meeting, Clin Canc Res, 2005 Jan; (11):421-28.
134.Mashour GA, Walker EE, Martuza RL. Psychosurgery: past, present, and future. Brain Res Brain
Res Rev. 2005 Jun;48(3):409-19.
135.Chan AW, Black P, Ojemann RG, Barker FG 2nd
, Kooy HM, Lopes VV, McKenna MJ, Shrieve
DC, Martuza RL, Loeffler JS. Stereotactic radiotherapy for vestibular schwannomas: favorable
outcome with minimal toxicity. Neurosurgery. 2005 Jul;57(1):60-70; discussion 60-70.
136.Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RI. Enhanced therapeutic efficiacy of
IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived
prostate cancers. Cancer Gene Therapy, 2005 Sept, (Advance Online Publication)
137.Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T. Oncolytic herpes simplex virus vector
g47delta in combination with androgen ablation for the treatment of human prostate
adenocarcinoma. Clin Cancer Res. 2005 Nov 1;11(21):7886-90.
138.Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T. Triple gene-deleted oncolytic herpes simplex
virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial
chromosome-mediated system. Cancer Res. 2005 Dec 1;65(23):10663-8.
139. Lui R, Martuza RL, Rabkin SD. Intracarotid delivery of oncolytic HSV vector G47∆ to
metastatic breast cancer in the brain, Gene therapy 2005 12, 647-654.
140.Aghi M, Rabkin S, Martuza RL. The effect of chemotherapy-induced DNA repair on oncolytic
herpes simplex viral replication. Journal of the National Cancer Institute, J Natl Cancer Inst. 2006
141.Varghese S Rabkin SD, Nielsen PG, Wang W, and Martuza RL. Systemic oncolytic herpes virus
therapy of poorly immunogenic prostate cancer metastatic to lung. Clinical Cancer Research (in
142.Messerli SM, Prabhakar S, Tang Y, Mahmood U, Weissleder R, Bronson R, Martuza R, Rabkin S,
Breakefield XO. Treatment of Schwannomas with an Oncolytic Recombinant Herpes Simplex
Virus in Murine Models of Neurofibromatosis Type 2. Hum Gene Ther. 2006 Jan 17: 20-30.
Books, Chapters, Monographs, Reviews, Other Publications
1. Martuza RL, Ojemann RG. Intracranial neoplasms. In Current Diagnosis. (Conn HF and
Conn RB Jr). WB Saunders Co., Philadelphia. 13: 895-902, 1980.
2. Martuza RL. Neurofibromatosis: neurological and neurosurgical considerations. Neurology
and Neurosurgery Update Series. Continuing Professional Education Center, Inc. 38(3), l982.
3. Martuza RL. Genetics in neuro-oncology. Clin Neurosurg. 31: 4l7-40, 1984.
4. Martuza RL. Neurofibromatosis and other phakomatoses. In Neurosurgery (Wilkins RH and
Rengachary SS). McGraw-Hill Book Co., NY. II(55): 511-21, 1984.
5. Martuza RL. Genetic factors in brain tumors. In Neurosurgery (Wilkins RH and Rengachary
SS). McGraw-Hill Book Co., NY. II(54): 505-ll, 1984.
6. Martuza RL. Parker SW. Nadol JB Jr. Davis KR. Ojemann RG. Diagnosis of cerebellopontine
angle tumors. Clin Neurosurg. 32: l77-2l3, 1985.
7. Martuza RL. Aquino T. Trauma. In Manual of Neurologic Therapeutics, Third Edition
(Samuels MA). Little, Brown, Co. Boston, MA. 1985.
8. Martuza RL. Seizinger BR. Jacoby LB. Rouleau GA. Gusella JF. The molecular biology of
human glial tumors. Trends in Neurosciences. 11(1): 22-7, 1988 Jan.
9. Martuza RL. Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). New
England Journal of Medicine. 318(11): 684-8, 1988 Mar 17.
10. Martuza RL. Neurosurgical aspects of neurofibromatosis. In Neurofibromatosis. In A
Handbook for Patients, Families, and Health Care Professionals (Rubenstein A and Korf B).
Thieme-Stratton Pub. Co.
11. Ojemann RG. Martuza RL. Acoustic neuroma. In Neurological Surgery, Third Edition
(Youmans J). WB Saunders Co., Philadelphia. Ch 113; 3316-50, 1990.
12. Chiocca EA. Martuza RL. Neurosurgical therapy of the obsessive-compulsive disorder. In
Obsessive Compulsive Disorders: Theory and Management, Second Edition (Jenike M, Baer L
and Minichiello WE). Year Book Medical Publishers, Inc., Chicago. 1990.
13. Fontaine B. Rouleau GA. Seizinger BS. Menon AG. Jewell AF. Martuza RL. Gusella JF.
Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and
meningioma). Ann NY Acad Sci. 615: 338-343, 1990.
14. Martuza RL. Rouleau G. Genetic aspects of neurosurgical problems. In Neurological
Surgery, Third Edition (Youmans J). WB Saunders Co., Philadelphia. Ch 38; 1061-1080,
15. Steichen JD. Martuza RL. Trauma. In Manual of Neurologic Therapeutics, Fourth Edition
(Samuels MA). Little, Brown, Co., Boston, MA. 1990.
16. Eldridge R. Martuza RL. Parry DM. Neurofibromatosis 2. In Current Therapy in Neurologic
Disease. (Johnson RT). B.C. Decker Inc., Philadelphia. 1990.
17. Martuza RL. Chiocca EA. Jenike MA. Giriunas I, Ballantine HT. Stereotactic radiofrequency
thermal cingulotomy for obsessive-compulsive disorder. J of Neuropsychiatry and Clinical
Neurosciences. 2(3): 331-6, 1990 Summer.
18. Martuza RL. Neurofibromatosis as a model for tumor formation in the human nervous system.
Neurobiology of Brain Tumors. Concepts in Neurosurgery. 4: 53-62, 1991.
19. Gusella JF. Seizinger BR. Rouseau G. Menon A. Fontaine B. Martuza RL. Molecular genetic
analysis of the phakomatoses. In Molecular Mechanisms and Their Clinical Applications in
Malignancies. Academic Press, Inc. 1991.
20. Martuza RL. Pathogenesis and treatment of nervous system tumors in NF2. In Tuberous
sclerosis and Neurofibromatosis: Epidemiology, Pathophysiology, Biology, and Management
(Ishibashi Y and Hori E). Elsevier Science Publishers B.V., Amsterdam. 1991.
21. Martuza RL. Genetic alterations of nervous system tumors. In Biologic Aspects of Brain
Tumors (Tabuchi). Springer-Verlag Inc., Tokyo. 18-27, 1991.
22. Short MP. Martuza RL. Clinical and genetic aspects of NF2: clinical features, family studies,
counseling, and management issues. In Neurofibromatosis (Hughes RAC and Huson ).
Chapman and Hall Ltd, London. 1991.
23. Martuza RL. Viral vectors for experimental brain tumor therapy. In Molecular Genetics
of Nervous System Tumors (Levine A and Schmidek H). 381-386.
24. Chiocca EA. Andersen JK. Takamiya Y. Martuza RL. Breakefield XO. Virus-mediated
genetic treatment of rodent gliomas. Gene Therapeutics (Wolff JA). Birkhauser Publishers,
Boston. 245-63, 1994.
25. Baer L. Rauch AL. Ballantine HT Jr. Martuza RL. Cosgrove R. et al. Cingulotomy for
intractable obsessive-compulsive disorder: prospective long-term follow-up of 18 patients.
Arch Gen Psych. 52(5): 384-92, 1995 May.
26. Hunter W. Rabkin S. Martuza RL. Brain tumor therapy using genetically engineered
replication competent virus. In Viral Vectors (Kaplitt MG and Loewy AD). Academic Press,
Inc., San Diego. 259-7, 1995.
27. Martuza RL. Proctor MR. Trauma. Manual of Neurologic Therapeutics (Samuels MA).
Little, Brown, Co., Boston, MA. 5th
revised edition: 250-76, 1995.
28. Viola JJ. Martuza RL. Gene therapies for glioblastomas. In Ballieres Clinical Neurology,
Cerebral Gliomas (Yung WKA). 5(2): 413-24, 1996 Jun.
29. Sampson JH. Martuza RL. Genetic factors in brain tumors. In Neurosurgery, Second Edition
(Wilkins RH and Rengachary SS). McGraw-Hill, New York. 665-71, 1996.
30. Sampson JH. Martuza RL. Neurofibromatosis and other phakomatoses. In Neurosurgery,
Second Edition (Wilkins RH and Rengachary SS). McGraw-Hill, New York. 673-685, 1996.
31. Hunter W. Yazaki T. Rabkin SD. Martuza RL. Replication-competent viral therapy of tumors
of the central nervous system. In Protocols for Gene Transfer in Neuroscience: Towards Gene
Therapy of Neurological Disorders (Lowenstein P and Enquist). Wiley and Sons Ltd. 305-17,
32. Martuza RL. Act locally, think globally. Nature Medicine. 3(12): 1323, 1997 Dec.
33. Lin TS. Martuza RL. Neurofibromatosis and other dysgenetic disorders. Handbook of
Clinical Neurology: Neuro-Oncology, Part II (Vecht ChJ). Elsevier Science B.V. 24(68):
34. Baidas S. Martuza RL. Tumors of the brain and spinal cord. Encyclopedia of Neuroscience.
Elsevier Science. 1998.
35. Martuza RL. Coumans JV CE. Trauma: Severe head Injury, Spinal Cord Injury. In Manual of
Neurologic Therapeutics, Sixth Edition (Samuels MA). Lippincott Williams & Wilkins,
Philadelphia, PA. Ch 12: 285-314, 1999.
36. Lin T. Martuza RL. Gliomas in neurofibromatosis and other phakomatoses. In The Gliomas
(Berger MS and Wilson C). W.B. Saunders Co., Philadelphia, PA. 15-24: 1999.
37. Feigenbaum F. Manz HJ. Platenberg LC. Martuza RL. Primary intrinsic tumors of the Brain.
In Principles of Neurosurgery (Grossman RG and Loftus CM). Lippincott-Raven Publishers,
Philadelphia, PA. 469-520: 1999.
38. Hunter WD. Martuza RL. Meningioma. Encyclopedia of Neuroscience. Elsevier Science.
39. Martuza RL. Conditionally-replicating herpes vectors for cancer therapy. J Clin Invest.
105(7): 841-6, 2000 Apr.
40. Kirn D. Martuza RL. Zwiebel J. Replication-selective virotherapy for cancer: Biological
principles, risk management and future directions. Nature Medicine. 7(7): 781-7, 2001 Jul.
41. Mashour GA,. Walker EE, Martuza RL,. Psychosurgery: Past, Present, and Future., Brain Res
Reviews. 48:409-419, 2005
42. Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, Drewes LR, Hall
WA, Hoffman JM, Korfel A, Martuza R, Muldoon LL, Peereboom D, Peterson DR, Rabkin
SD, Smith Q, Stevens GH, Neuwelt EA. New frontiers in translational research in neuro-
oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier
Disruption Consortium Meeting. Clin Cancer Res 2005 Jan 15; 11: 421-428, '05
43. Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene. 2005 Nov